DuPont Soars to Lead the Dow's Comeback

After yesterday's market bloodbath, DuPont and Merck are among a handful of high-performing stocks on the Dow Jones today.

Feb 4, 2014 at 2:31PM

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

After yesterday's market implosion, the Dow Jones Industrial Average (DJINDICES:^DJI)has turned things around to pick up about 70 points as of 2:30 p.m., with most blue-chip stocks rising into the green. DuPont's (NYSE:DD) 3% leap has led the Dow, while Big Pharma company Merck (NYSE:MRK) has risen 2.7% after signing a big deal of it own. Let's catch up on what you need to know.

DuPont hones in on farming dominance
DuPont is a huge player in the agricultural industry, and today the company's seed business announced a new deal with information firm DTN/The Progressive Farmer. The agreement will allow DuPont to send out weather and market information to farmers, expanding the company's reach in the growing precision agriculture industry that's centered around using data and analytics to maximize farm profits on such trends as soil types, moisture, and weather patterns.

DuPont's deal comes after rival Monsanto (NYSE:MON) signed a similar agreement in November, buying The Climate Corp., a weather data company, for $930 million. Monsanto projects that data mapping in agriculture could unlock a new $20 billion market.

That's a gold mine for DuPont, which has struck it rich in the agricultural sector as of late. The company announced a strikingly successful most recent quarter, doubling its net profit and growing sales nearly 6% behind its surging agricultural unit. The business has become DuPont's largest by sales, and in the fourth quarter revenue from agricultural products jumped 18%. Latin America has exploded as a major growth market, with insecticides selling very well in the most recent quarter. If DuPont can become a dominant force in the precision agriculture industry, this company will be poised to see a lot more green for a long time in its largest business.

Merck's also moving up in a big way today after the company announced an agreement with Belgian biotech Ablynx to develop new cancer treatments. The deal, in which Merck will pay $27 million up front to the company but could deliver up to $2.3 billion if more conditions are met, will see Ablynx develope its nanobodies to pursue more effective cancer immunotherapies. Merck has pushed into the cancer-fighting therapy market at full steam, recently filing for approval for its potential blockbuster drug MK-3475. Considering that analysts believe the cancer immunotherapy market could be worth up to $35 billion eventually, Merck may be on the way to restocking its pipeline with some serious potential firepower.

Can Merck's dividend transform your financial future?
Merck's emerged as a top dividend stock on the Dow with its high yield. One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers